This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Intuitive Surgical Banks on da Vinci X, Forex Woes Remain
by Zacks Equity Research
Intuitive Surgical's (ISRG) consistent efforts to boost da Vinci X platform is a positive. However, foreign exchange movements are impacting the company's results
PerkinElmer (PKI) Closes EUROIMMUN Acquisition for $1.3B
by Zacks Equity Research
PerkinElmer (PKI) focuses on inorganic growth through acquisition.
DexCom (DXCM) Banks on Collaborations, Competition Rife
by Zacks Equity Research
DexCom's (DXCM) collaborative agreements should bring in cash in the form of milestone payments and royalties, and help expand product portfolio.
NuVasive (NUVA) Global Prospects Solid, Pricing Woes Remain
by Zacks Equity Research
NuVasive (NUVA) witnesses solid top-line contributions from the international business.
Innovation, Partnership Aid Genomic Health, Cost Woe Remains
by Zacks Equity Research
Genomic Health's (GHDX) recent positive finds from a string of 10 trials on Oncotype DX Breast Recurrence Score test are likely to buoy investors' optimism.
TransEnterix & GBIL Ink Deal to Commercialize SurgiBot System
by Zacks Equity Research
TransEnterix (TRXC) to retain distribution rights of SurgiBot System outside China.
Amedisys (AMED) Banks on Personal Care Amid Margin Woes
by Zacks Equity Research
Amedisys' (AMED) efforts have helped turn around the Personal Care business.
Ecolab, Cargill and Techstars Launch Accelerator Program
by Zacks Equity Research
Ecolab (ECL) continues to focus on investment in key businesses and bolt-on acquisitions to gain market traction and boost profits.
Express Scripts Buys eviCore for $3.6B, Forays Into MBM
by Zacks Equity Research
The eviCore buyout boosts Express Scripts' (ESRX) ability to drive value in the use of Specialty medications.
Genomic Health at a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Genomic Health (GHDX) forges ahead with deals to strengthen hold in the high-potential prostate cancer therapeutics market.